PURPOSE: To measure the relative efficacy of brinzolamide hydrochloride 1% ophthalmic
suspension, a new carbonic anhydrase inhibitor, compared with the currently used …

Objective To measure the effect of topically applied 2% dorzolamide hydrochloride (Trusopt,
Merck & Co Inc, Whitehouse Station, NJ) and different doses of orally administered …

Objective: To compare the efficacy of topical 2% dorzolamide hydrochloride (Trusopt) as a
suppressor of aqueous humor flow in the human eye with the efficacy of systemically …

Objectives To measure the effectiveness of topical 0.2% brimonidine tartrate asa suppressor
of aqueous humor flow in the human eye compared with the effectivenessof 2% dorzolamide …

This study examines the mechanisms by which brinzolamide reduces intraocular pressure
(IOP) in healthy rabbits and in monkeys with unilateral ocular hypertension. Intraocular …

OBJECTIVE: The purpose of the study was to measure the effect of the topical carbonic
anhydrase inhibitor, 2% dorzolamide hydrochloride, on the rate of aqueous humor flow in …

PURPOSE: To determine whether latanoprost, an ocular hypotensive agent believed to
enhance uveoscleral outflow of aqueous humor, augments the aqueous-suppressing effect …

Abstract· Purpose: The topical carbonic anhydrase inhibitor dorzolamide has proven
effective in lowering intraocular pressure in glaucoma patients. Because an impaired blood …

Objectives: To measure the effectiveness of topical 2% dorzolamide hydrochloride (Trusopt,
Merck & Co Inc, Whitehouse Station, NJ) as a suppressor of aqueous humor flow in the …

Purpose: To study the effect of a single dose of topical dorzolamide hydrochloride 2%, a
carbonic anhydrase inhibitor, on the retinal circulation of normal subjects. Methods …